In Situ Vaccination with An Injectable Nucleic Acid Hydrogel for Synergistic Cancer Immunotherapy
Angewandte Chemie International Edition · 2024
DOI: 10.1002/anie.202315282 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2024. Verfasst von Fujun Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering, Frontiers Science Center for Transformative Molecules, Shanghai Key Laboratory for Molecular Engineerin…. Hauptthemen laut MEDLINE: Nucleic Acids, Melanoma, Vaccines. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shanghai Sailing Program.
Abstract (Originalsprache)
Recently, therapeutic cancer vaccines have emerged as promising candidates for cancer immunotherapy. Nevertheless, their efficacies are frequently impeded by challenges including inadequate antigen encapsulation, insufficient immune activation, and immunosuppressive tumor microenvironment. Herein, we report a three‐in‐one hydrogel assembled by nucleic acids (NAs) that can serve as a vaccine to in situ trigger strong immune response against cancer. Through site‐specifically grafting the chemodrug, 7‐ethyl‐10‐hydroxycamptothecin (also known as SN38), onto three component phosphorothioate (PS) DNA strands, a Y‐shaped motif (Y‐motif) with sticky ends is self‐assembled, at one terminus of which an unmethylated cytosine‐phosphate‐guanine (CpG) segment is introduced as an immune agonist. Thereafter, programmed cell death ligand‐1 (PD‐L1) siRNA that performs as immune checkpoint inhibitor is designed as a crosslinker to assemble with the CpG‐ and SN38‐containing Y‐motif, resulting in the formation of final NA hydrogel vaccine. With three functional agents inside, the hydrogel can remarkably induce the immunogenic cell death to enhance the antigen presentation, promoting the dendritic cell maturation and effector T lymphocyte infiltration, as well as relieving the immunosuppressive tumor environment. When inoculated twice at tumor sites, the vaccine demonstrates a substantial antitumor effect in melanoma mouse model, proving its potential as a general platform for synergistic cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Chemical Engineering, Frontiers Science Center for Transformative Molecules, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, Shanghai Jiao Tong University, Shanghai, 200240, Ch…
- Institute of Molecular Medicine, Shanghai Jiao Tong University Affiliated Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
- Department of Radiology, Shanghai Jiao Tong University School of Medicine Affiliated Shanghai Sixth People's Hospital, 600 Yi Shan Road, Shanghai, 200233, P. R. China.
ORCID-Profile: Chuan Zhang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Shanghai Sailing Program
- Natural Science Foundation of Shanghai
- Shandong Provincial Natural Science Foundation
- Shanghai Pilot Program for Basic Research-Shanghai Jiao Tong University
- Natural Science Foundation of Shandong Province
Zitieren
APA
Wang, F., Xie, M., Huang, Y., Liu, Y., Liu, X., Zhu, L., Zhu, X., Guo, Y., & Zhang, C. (2024). In Situ Vaccination with An Injectable Nucleic Acid Hydrogel for Synergistic Cancer Immunotherapy. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202315282
Vancouver
Wang F, Xie M, Huang Y, Liu Y, Liu X, Zhu L, et al. In Situ Vaccination with An Injectable Nucleic Acid Hydrogel for Synergistic Cancer Immunotherapy. Angewandte Chemie International Edition. 2024. doi:10.1002/anie.202315282
BibTeX
@article{Wang2024,
author = {Wang, Fujun and Xie, Miao and Huang, Yangyang and Liu, Yuhe and Liu, Xinlong and Zhu, Lijuan and Zhu, Xinyuan and Guo, Yuanyuan and Zhang, Chuan},
title = {In Situ Vaccination with An Injectable Nucleic Acid Hydrogel for Synergistic Cancer Immunotherapy},
journal = {Angewandte Chemie International Edition},
year = {2024},
doi = {10.1002/anie.202315282}
}
EUVIMED